KDC-MN-134 – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

PEG-MGF is a pegylated form of mechano-growth factor, a splice variant of IGF-1 produced in muscle in response to mechanical loading. The PEG group extends the half-life from minutes to days. Used in research for satellite cell activation and muscle repair. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

40/100

Interesting local IGF-1 splice variant biology for muscle repair, but preclinical-only with limited independent replication

The biology here is genuinely interesting. MGF (mechano growth factor) is the locally-produced splice variant of IGF-1 (IGF-1Ec) that muscles generate in response to mechanical damage. Unlike systemic IGF-1, it carries a unique 24-residue C-terminal extension produced by alternative splicing of exon 5, and that E-peptide fragment appears to activate muscle satellite cells through a mechanism that doesn’t require IGF-1 receptor engagement. Geoffrey Goldspink’s lab at UCL established most of the foundational work, and the core biology is elegant: mechanical loading triggers local MGF expression, which recruits quiescent satellite cells into the repair cycle upstream of systemic IGF-1 signaling.

Pegylation addresses the most obvious problem with native MGF, which clears from plasma in minutes. Attaching a polyethylene glycol moiety extends the half-life to hours in animal models, making sustained satellite cell engagement more pharmacologically plausible. In rodent studies, PEG-MGF has shown increased satellite cell number, improved muscle cross-sectional area after damage, and some preservation of muscle mass in aging models. The signal is real enough to take seriously at the preclinical level.

Here’s the thing though: the literature is thin and concentrated. Goldspink’s group produced a disproportionate share of the foundational MGF research, and independent replication of PEG-MGF specifically is sparse. Human data is essentially nonexistent at this point. The compound lives in the same research peptide ecosystem as BPC-157 and TB-500, and it shares those compounds’ core problem: compelling preclinical biology that hasn’t crossed into well-powered human trials. The satellite cell activation story is mechanistically cleaner than BPC-157’s polyvalent mechanism, but the evidence base is actually narrower, not wider.

What we like as a research tool: PEG-MGF is a useful probe for studying the IGF-1Ec axis specifically, and for distinguishing local vs. systemic IGF-1 effects in muscle repair models. If you’re running satellite cell biology, this compound lets you ask questions you can’t ask with systemic IGF-1 or conventional GHRPs. Thats a real niche. The E-peptide receptor question (whether it engages something distinct from IGF-1R) remains open and is genuinely worth pursuing at the bench.

What we dont like: sourcing quality is variable across the research peptide market, pegylation adds synthesis complexity that translates to real vendor-to-vendor inconsistency in purity and conjugation degree, and the dose-response relationship in rodent models isn’t cleanly established even within the existing literature. For a lab running a dedicated satellite cell or muscle repair program, PEG-MGF makes sense in vitro. For most programs, the thin and concentrated evidence base makes it a secondary priority behind compounds with broader replication behind them.

Novelty: 40
Mechanism promise: 58
In-category differentiation: 40
Evidence quality: 28
Translational signal: 22
Research bench value: 45

Rationale Goldspink’s UCL group produced a disproportionate share of the foundational MGF literature, and independent PEG-MGF replication is sparse; the E-peptide satellite cell activation biology is mechanistically compelling but human evidence is essentially absent, placing this compound alongside BPC-157 in the single-lab-only tier at the lower end of that range.

Pegylated IGF-1 splice variant

A pegylated form of mechano growth factor (the IGF-1Ec splice variant) sold as a research peptide for muscle repair applications.

Abstract

PEG-MGF is a pegylated form of mechano growth factor (MGF), a splice variant of IGF-1 (IGF-1Ec) generated by exercise-induced muscle damage. MGF differs from systemic IGF-1 in containing a unique 24-residue C-terminal extension produced by alternative splicing of exon 5. The MGF C-terminal peptide alone (without the IGF-1 mature peptide) has been studied for muscle stem cell activation. Pegylation extends plasma half-life of the otherwise rapidly cleared peptide. The compound is sold as a research peptide; clinical evidence base in humans is sparse.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-134Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-134

PEG-MGF (Mechano Growth Factor)

Abstract

Read the full monograph